Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25396399 | 1.00 | DRD4 (0.85) | DRD4HRH3 | |
| Bromide SCHEMBL30589863 | 0.99 | DRD4 (0.83) | DRD4HRH3 | |
| Bromide SCHEMBL30589855 | 0.99 | DRD4 (0.83) | DRD4HRH3 | |
| Hydrochloric Acid SCHEMBL25397740 | 0.99 | DRD4 (0.83) | DRD4HRH3 | |
| SCHEMBL6164051 | 0.92 | DRD4 (1.00) | DRD4 | |
| Oxalic Acid SCHEMBL6162010 | 0.88 | DRD4 (0.88) | DRD4 | |
| SCHEMBL6162444 | 0.86 | DRD4 (1.00) | DRD4 | |
| SCHEMBL4502566 | 0.85 | DRD4 (0.74) | DRD4 | |
| Oxalic Acid SCHEMBL7648434 | 0.85 | DRD4 (0.89) | DRD4 | |
| SCHEMBL16976478 | 0.85 | DRD4 (0.64) | DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2026-03-19 | — | — | US | disclosed |
| US-20260062395-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | CURIA SPAIN S A U (ES) | 2026-03-05 | — | — | US | disclosed |
| EP-4565571-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2025-06-11 | — | — | EP | disclosed |
| CN-119768395-A | Processes and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives | 库里亚西班牙公司 | 2025-04-04 | — | — | CN | disclosed |
| EP-4493550-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | Supernus Pharmaceuticals, Inc. (US) | 2025-01-22 | — | — | EP | disclosed |
| US-11964951-B2 | Process of making derivatives of substituted morpholines | SUPERNUS PHARMACEUTICALS, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| WO-2024028423-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | CURIA SPAIN, S.A.U. (ES) | 2024-02-08 | — | — | WO | disclosed |
| EP-4317141-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | Curia Spain S.A.U. (ES) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-11-09 | — | — | US | disclosed |
| WO-2023177845-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | SUPERNUS PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | WO | disclosed |
| US-9403783-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403783-B2 | Methods for producing viloxazine salts and novel polymorphs thereof | SUPERNUS PHARMACEUTICALS, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| EP-2558437-B1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC (US) | 2015-08-05 | — | — | EP | disclosed |
| US-20150126735-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2015-05-07 | — | — | US | disclosed |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2011-10-13 | — | — | US | disclosed |
| EP-0920423-B1 | DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROSEARCH AS (DK) | 2005-01-26 | — | — | EP | disclosed |
| US-6479491-B1 | USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, ESPECIALLY PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA | NEUROSEARCH A/S (DK) | 2002-11-12 | — | — | US | disclosed |
| US-6207662-B1 | USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA | NEUROSEARCH A/S (DK) | 2001-03-27 | — | — | US | disclosed |
| EP-0920423-A1 | DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROSEARCH A/S (DK) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998007710-A1 | DISUBSTITUTED MORPHOLINE, OXAZEPINE OR THIAZEPINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS DOPAMINE D4 RECEPTOR ANTAGONISTS | NEUROSEARCH A/S (DK) | 1998-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11964951-B2 | Process of making derivatives of substituted morpholines | UGT2B7, CYP3A7, CYP3A4 | DRD4 160/4885HRH3 3933/4885 |
| US-20260078098-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | HTR2C, SLC6A2, HTR1D | DRD4 64/4885HRH3 411/4885 |
| US-20230357173-A1 | PROCESS OF MAKING DERIVATIVES OF SUBSTITUTED MORPHOLINES | UGT2B7, CYP3A7, CYP3A4 | DRD4 160/4885HRH3 3933/4885 |
| US-20260062395-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF VILOXAZINE AND OTHER 2-SUBSTITUTED MORPHOLINE DERIVATIVES | OGFRL1, SALL4, OGFR | DRD4 2218/4885HRH3 2845/4885 |
| US-20150126735-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | DRD4 722/4885HRH3 621/4885 |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | DRD4 722/4885HRH3 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.